The US Food and Drug Administration (FDA) has approved several systemic therapies including anti-angiogenic agents, mammalian target of Rapamycin (mTOR) inhibitors, and immunotherapeutic agents for the treatment of RCC (8). The gene discussed is MTOR; the disease is renal cell carcinoma.